Bank of New York Mellon Corp grew its stake in Exelixis, Inc. (NASDAQ:EXEL) by 2.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,207,459 shares of the biotechnology company’s stock after buying an additional 25,946 shares during the quarter. Bank of New York Mellon Corp’s holdings in Exelixis were worth $36,706,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in EXEL. Vident Investment Advisory LLC acquired a new stake in shares of Exelixis during the 3rd quarter worth about $783,000. Keybank National Association OH raised its position in shares of Exelixis by 114.3% during the 4th quarter. Keybank National Association OH now owns 44,793 shares of the biotechnology company’s stock worth $1,362,000 after acquiring an additional 23,893 shares in the last quarter. Schroder Investment Management Group acquired a new stake in shares of Exelixis during the 3rd quarter worth about $334,000. Strs Ohio acquired a new stake in shares of Exelixis during the 4th quarter worth about $7,144,000. Finally, James Investment Research Inc. raised its position in shares of Exelixis by 21.4% during the 4th quarter. James Investment Research Inc. now owns 74,655 shares of the biotechnology company’s stock worth $2,270,000 after acquiring an additional 13,155 shares in the last quarter. Institutional investors and hedge funds own 80.55% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several brokerages have recently weighed in on EXEL. Oppenheimer reissued a “hold” rating on shares of Exelixis in a research report on Wednesday, January 17th. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 target price on the stock in a research report on Tuesday, January 2nd. BidaskClub lowered Exelixis from a “buy” rating to a “hold” rating in a research report on Thursday, March 1st. Cann reissued a “buy” rating and set a $40.00 target price on shares of Exelixis in a research report on Thursday, March 8th. Finally, ValuEngine lowered Exelixis from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $34.10.

Exelixis, Inc. (NASDAQ:EXEL) opened at $24.80 on Wednesday. The company has a market capitalization of $7,340.00, a P/E ratio of 50.61, a price-to-earnings-growth ratio of 1.29 and a beta of 1.96. Exelixis, Inc. has a 12-month low of $18.03 and a 12-month high of $32.50.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 EPS for the quarter, hitting the consensus estimate of $0.12. The company had revenue of $120.10 million for the quarter, compared to analyst estimates of $120.25 million. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The firm’s revenue was up 54.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 earnings per share. research analysts predict that Exelixis, Inc. will post 0.59 earnings per share for the current fiscal year.

In other Exelixis news, Director Vincent T. Marchesi sold 15,000 shares of Exelixis stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $24.73, for a total transaction of $370,950.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lance Willsey sold 30,000 shares of Exelixis stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $23.91, for a total value of $717,300.00. Following the transaction, the director now directly owns 483,273 shares in the company, valued at approximately $11,555,057.43. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 120,029 shares of company stock worth $3,158,287. 5.10% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Bank of New York Mellon Corp Buys 25,946 Shares of Exelixis, Inc. (EXEL)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/03/14/bank-of-new-york-mellon-corp-buys-25946-shares-of-exelixis-inc-exel.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.